REGULAR CONTENT
Final ID
524
Type
Original Scientific Research-Poster Only
Authors
C Selph1, G Glaun1, F Weber2, C Johnson3
Institutions
1University of Central Florida College of Medicine, Orlando, FL, 2Nemours Children's Hospital, Orlando, FL, 3Nemours Foundation, Orlando, FL
Purpose
To determine if the inflammatory seromas observed following the replacement of room air with CO2 gas during sclerotherapy of venous malformations are positive prognostic indicators. Specifically, to determine whether these inflammatory seromas predict decreased treatment time to goal and decreased recurrence rates.
Materials & Methods
Retrospective case series of 9 patients who received sclerotherapy of VMs using sclerosant foam containing CO2 gas in place of room air. Volume reduction, level of pain, length of hospital stay, cost, radiation dose, and time to treatment goal were measured.
Results
9 patients were discovered to have an inflammatory seroma in response to CO2 –infused sclerosant foam. They appeared larger than baseline and were not self-resolving but were painless and sterile. As opposed to staged treatments needed with the room air based sclerosants, the inflammatory seromas required only one short drainage procedure before resolution of VM. Occlusion of inflow and outflow tracts was seen with inflammatory seromas post-CO2 sclerotherapy but was not seen with the room air equivalent. Inflammatory seromas appear to be a positive prognostic indicator as they lead to decreased hospital stay, cost, pain, radiation dose, and treatment time to goal. Limitations include only a subset of patients receiving CO2-based sclerotherapy resulting in an inflammatory seroma, and this treatment requires the ability to store CO2 gas.
Conclusions
Inflammatory seromas seen only after CO2-infused sclerotherapy of VMs are positive prognostic indicators of which this is the first description of this finding. Prospectively, these patients should be followed long-term to determine long-term efficacy and recurrence rate of room air-based sclerosant vs. CO2-based sclerosant.
Final ID
524
Type
Original Scientific Research-Poster Only
Authors
C Selph1, G Glaun1, F Weber2, C Johnson3
Institutions
1University of Central Florida College of Medicine, Orlando, FL, 2Nemours Children's Hospital, Orlando, FL, 3Nemours Foundation, Orlando, FL
Purpose
To determine if the inflammatory seromas observed following the replacement of room air with CO2 gas during sclerotherapy of venous malformations are positive prognostic indicators. Specifically, to determine whether these inflammatory seromas predict decreased treatment time to goal and decreased recurrence rates.
Materials & Methods
Retrospective case series of 9 patients who received sclerotherapy of VMs using sclerosant foam containing CO2 gas in place of room air. Volume reduction, level of pain, length of hospital stay, cost, radiation dose, and time to treatment goal were measured.
Results
9 patients were discovered to have an inflammatory seroma in response to CO2 –infused sclerosant foam. They appeared larger than baseline and were not self-resolving but were painless and sterile. As opposed to staged treatments needed with the room air based sclerosants, the inflammatory seromas required only one short drainage procedure before resolution of VM. Occlusion of inflow and outflow tracts was seen with inflammatory seromas post-CO2 sclerotherapy but was not seen with the room air equivalent. Inflammatory seromas appear to be a positive prognostic indicator as they lead to decreased hospital stay, cost, pain, radiation dose, and treatment time to goal. Limitations include only a subset of patients receiving CO2-based sclerotherapy resulting in an inflammatory seroma, and this treatment requires the ability to store CO2 gas.
Conclusions
Inflammatory seromas seen only after CO2-infused sclerotherapy of VMs are positive prognostic indicators of which this is the first description of this finding. Prospectively, these patients should be followed long-term to determine long-term efficacy and recurrence rate of room air-based sclerosant vs. CO2-based sclerosant.